703 filings
Page 11 of 36
POS AM
v1kox0j
13 Mar 17
Prospectus update (post-effective amendment)
12:00am
POS AM
uewhhth6rz4 suixk
13 Mar 17
Prospectus update (post-effective amendment)
12:00am
8-A12G/A
juuofdbq c4
7 Mar 17
Registration of securities (amended)
12:00am
8-K
39cdcql7kacwk7sw
24 Feb 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
a5fd0
13 Jan 17
Departure of Directors or Certain Officers
12:00am
UPLOAD
soup 00k7
6 Jan 17
Letter from SEC
12:00am
8-K
npsr76338 6wf7o
6 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
qw1fft lw
19 Dec 16
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
12:00am
424B5
hbfpvvlrc
14 Dec 16
Prospectus supplement for primary offering
12:00am
424B5
rkux8j9pdu6ufdb
14 Dec 16
Prospectus supplement for primary offering
12:00am
8-K
ljadgf0227tej dq3mg
14 Dec 16
CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock
12:00am
8-K
a7nh izps
2 Dec 16
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors
12:00am
8-K
fna2h3g3lh33
29 Nov 16
CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas
12:00am
8-K
aeokb 5bs94ahx
14 Nov 16
Unregistered Sales of Equity Securities
12:00am
8-K
lo2ky1xa9
9 Nov 16
CytRx Reports Third Quarter 2016 Financial Results
12:00am
8-K
kwotqs ear8f9j5n6r76
19 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
lr4ud
26 Aug 16
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
S-8
28jnpn1
5 Aug 16
Registration of securities for employees
12:00am